Novo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk

Dow Jones

11/05

0924 GMT - Novo Nordisk's narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

November 05, 2025 04:24 ET (09:24 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581674233"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581674233\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581674233?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581674233","market":"sh","top_or_hot":-1,"title":"Novo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0924 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 04:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Narrowed Guidance Suggests Consensus Sales Downgrades -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-05 17:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0924 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 04:24 ET (09:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581674233","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581674233","pubTimestamp":1762334640,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0924 GMT - Novo Nordisk's narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德缩小的指引表明普遍销售评级下调——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5},"content_text":"0924 GMT - Novo Nordisk's narrowed outlook to the bottom end of the range suggests up to 3 percentage points of consensus sales downgrades, analysts at Jefferies write. Underlying consensus operating profit downgrades are likely to be smaller than this though, as estimates probably didn't take into account the Danish pharmaceutical company's recently announced restructuring and associated costs, they add. Third-quarter sales missed expectations by 2%, with Wegovy 3% light and Rybelsus a 7% miss while Ozempic sales are 2% ahead due to one-offs. A significantly weaker gross margin but lower operating expenditure leaves EBIT 8% below consensus, albeit likely skewed by estimates from prior to the restructuring announcement, Jefferies says. Shares rise 1.7%. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 04:24 ET (09:24 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}